Zoetis

Zoetis, a US-headquartered Pharmaceutical Preparation Manufacturing company, reported its 2025 carbon emissions. The company's Scope 1 emissions were 122,311,000 kg CO2e, with mobile combustion accounting for 22,962,000 kg CO2e. Its Scope 2 market-based emissions were 27,069,000 kg CO2e, and location-based Scope 2 emissions were 121,287,000 kg CO2e. Scope 3 emissions included 24,126,000 kg CO2e from business travel and 13,529,000 kg CO2e from employee commute. Data for Scope 3 purchased goods and services was not available.

Looking back, in 2024, Zoetis's Scope 1 emissions were 107,033,000 kg CO2e, Scope 2 market-based emissions were 30,707,000 kg CO2e, and Scope 3 emissions from business travel and employee commute were 24,620,000 kg CO2e and 13,825,000 kg CO2e, respectively. In 2023, Scope 1 emissions totalled 105,549,000 kg CO2e, Scope 2 market-based emissions were 79,537,000 kg CO2e, and Scope 3 business travel and employee commute emissions were 21,367,000 kg CO2e and 13,556,000 kg CO2e.

Zoetis has set a near-term goal to become carbon neutral in its own operations (Scope 1 and 2 emissions) by 2030, with a focus on manufacturing, R&D, office locations, and fleet vehicles. The company also aims for a 5% reduction in energy intensity in manufacturing and research and development by 2025, using a 2019 baseline, for both Scope 1 and Scope 2 emissions. As of 2023, Zoetis reported an 18.9% reduction in Scope 1 and 2 emissions towards its 2030 carbon neutrality target.